03:41 AM EDT, 08/13/2024 (MT Newswires) -- Citius Pharmaceuticals ( CTXR ) said late Monday it has completed the pending merger of its oncology subsidiary and blank check firm TenX Keane Acquisition (TENK).

The combined company has been renamed Citius Oncology ( TENK ), with its stock expected to debut on Nasdaq on Aug. 13 under the ticker, "CTOR."

Pursuant to the deal, Citius Pharmaceuticals ( CTXR ) owns about 90% equity of Citius Oncology ( TENK ).

Price: 0.6798, Change: -0.01, Percent Change: -1.65